On 2016 Mar 29, Ludovic Barault commented:
Hi, People who are interesting in this research area should also read some of the recent studies (from our lab and others) currently unreferenced in the above manuscript:
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. PMID: 26916096
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. PMID: 26538496
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. PMID: 26113646
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. PMID: 24379162
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. PMID: 23443801
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. PMID: 23422094
Works from B. Kaina's lab
Sincerely,
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.